Revelation Biosciences Stock Today

REVB Stock  USD 1.62  0.06  3.57%   


0 of 100

Very Weak

Odds Of Distress

Over 85

Very High
Revelation Biosciences is trading at 1.62 as of the 23rd of July 2024, a 3.57 percent decrease since the beginning of the trading day. The stock's open price was 1.68. Revelation Biosciences has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Revelation Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of June 2024 and ending today, the 23rd of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
17th of November 2020
Health Care
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company was founded in 2020 and is based in San Diego, California. Revelation Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.63 M outstanding shares of which 84.45 K shares are at this time shorted by private and institutional investors with about 0.05 trading days to cover. More on Revelation Biosciences

Moving against Revelation Stock

  0.39PFE Pfizer Inc Earnings Call This WeekPairCorr
  0.33EWTX Edgewise TherapeuticsPairCorr
  0.33RVMD Revolution MedicinesPairCorr

Revelation Stock Highlights

Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Total Current Liabilities5.3 M5.6 M
Notably Down
Slightly volatile
Total Assets11.6 M12.2 M
Notably Down
Slightly volatile
Total Current Assets11.5 M12.1 M
Notably Down
Slightly volatile
Debt Levels
Revelation Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Revelation Biosciences' financial leverage. It provides some insight into what part of Revelation Biosciences' total assets is financed by creditors.
Revelation Biosciences currently holds 5.56 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Revelation Biosciences has a current ratio of 0.67, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Revelation Biosciences' use of debt, we should always consider it together with its cash and equity.

Capital Expenditures

Revelation Biosciences (REVB) is traded on NASDAQ Exchange in USA. It is located in 4660 La Jolla Village Drive, San Diego, CA, United States, 92122 and employs 9 people. Revelation Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.74 M. Revelation Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.63 M outstanding shares of which 84.45 K shares are at this time shorted by private and institutional investors with about 0.05 trading days to cover. Revelation Biosciences currently holds about 3.48 M in cash with (7.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15.
Check Revelation Biosciences Probability Of Bankruptcy
Ownership Allocation
Roughly 99.0 pct. of Revelation Biosciences outstanding shares are held by general public with 0.3239999999999999 % owned by insiders and only 0.52 (%) by third-party entities.
Check Revelation Ownership Details

Revelation Stock Institutional Holders

InstituionRecorded OnShares
Ubs Group Ag2024-03-31
4.2 K
Tower Research Capital Llc2024-03-31
3.1 K
Advisor Group Holdings, Inc.2024-03-31
Royal Bank Of Canada2024-03-31
Morgan Stanley - Brokerage Accounts2024-03-31
Wells Fargo & Co2024-03-31
Susquehanna International Group, Llp2023-12-31
Pom Investment Strategies, Llc2024-03-31
View Revelation Biosciences Diagnostics

Revelation Biosciences Historical Income Statement

At present, Revelation Biosciences' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 13.5 M, whereas Gross Profit is projected to grow to (23.8 K). View More Fundamentals

Revelation Stock Against Markets

Revelation Biosciences Corporate Management

James RolkeCEO DirectorProfile
Carol OdleDirector ProjectsProfile
Chester IIIChief OfficerProfile
Sandra VedrickVice RelationsProfile

Additional Information and Resources on Investing in Revelation Stock

When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Return On Assets
Return On Equity
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.